18F-FLUC-CEST PET/MR in Patients With Brain Mets

University of Wisconsin (UW)

Status and phase: Enrolling; Phase 3

Conditions: Immunotherapy, Active; Radiation Therapy; Brain Metastasis

Treatments: Radiation: F-Fluciclovine radiotracer

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT06159335

Protocol Version 2/12/2024 (Other Identifier)

A539300 (Other Identifier)

2023-1082

UW23061 (Other Identifier)

Details and patient eligibility

About

The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining.

Participants will undergo a single PET/MRI scan, followed by a separate MRI scan with a tracer. Study participation will last about 3 hours.

Full description

The purpose of this research is to utilize new imaging methods to aid in assessing whether imaging shows presence of tumor. Developing imaging technologies is critical for more accurately identifying location and amount of tumor, which will then lead to improvements in future cancer therapy.

This study aims to evaluate imaging methods known as PET and MRI to improve detection of cancerous tissue better than the types of imaging that are currently available.

These methods are conducted on the same machine as conventional MRI that uses a powerful magnet, radio waves, and a computer to create detailed images. Both the PET and MRI methods look at the number of proteins a tumor has. The more proteins, the more likely there is tumor relative to normal brain tissue.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years or older
• Able and willing to provide informed consent
• Has a brain metastasis diagnosis with at least one single visible contrast enhancing metastatic lesion on brain MRI
• Received at least one immune checkpoint inhibitor for treatment of the malignancy in the past 6 months
• Any other concurrent therapy or prior administered therapy, which would include prior surgery, radiation, immunotherapy, or chemotherapy are not an exclusion.
• Has had at least one previous standard-of-care MRI imaging within the past 60 days for assessment of disease location and extent with increasing enhancement where the question of tumor recurrence versus treatment related change are a clinical question.
• Be able to lie still for 30-60 minutes during the imaging procedure
• Willing and able to undergo PET/MRI

Exclusion criteria

• Subject unable or unwilling to provide informed consent
• Subject is pregnant
• Subject with contraindication(s) to or inability to undergo a PET or MRI
• Known allergy to 18F-Fluciclovine or any of its excipients

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

PET-MRI

Experimental group

Description:

Participants will undergo F-Fluciclovine PET radiotracer and MRI

Treatment:

Radiation: F-Fluciclovine radiotracer